Recombinant Human Neuregulin1‐β1 Significantly Reduces Schwannoma Growth in Mice
These findings highlight the therapeutic potential of rhNRG1-β1 in managing schwannomas, not only by reducing tumor growth, but also by promoting the maturation and functional restoration of Schwann cells. This dual effect provides a promising avenue for novel therapeutic strategies aimed at addressing both the growth and cellular differentiation challenges associated with schwannomas in NF2-SWN and other related conditions. ANN NEUROL 2026;99:369-381.
Authors
- Helen Morrison (ORCID: https://orcid.org/0000-0003-4938-1409)
- Waylan Bessler (ORCID: https://orcid.org/0000-0003-0685-9206)
- Christian Hagel (ORCID: https://orcid.org/0000-0003-0518-0824)
- Alexander Schulz (ORCID: https://orcid.org/0000-0003-1604-4596)
- R. Büttner (ORCID: https://orcid.org/0000-0002-4337-4251)
- M. Reuter (ORCID: https://orcid.org/0000-0003-3881-8310)
- Julia Bischoff
- D. Wade Clapp (ORCID: https://orcid.org/0000-0001-9465-0917)
Institutions
- Universität Hamburg (DE)
- University Medical Center Hamburg-Eppendorf (DE)
- Leibniz Institute on Aging - Fritz Lipmann Institute (FLI) (DE)
- Indiana University – Purdue University Indianapolis (US)
- Friedrich Schiller University Jena (DE)
Publication Details
- Journal
- Annals of Neurology
- Published
- 2025-10-17
- DOI
- https://doi.org/10.1002/ana.78050
- Primary Topic
- Neurofibromatosis and Schwannoma Cases
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Deutsche Forschungsgemeinschaft